title: Targeted transarterial therapy of Vx-2 rabbit liver tumor with Yttrium-90 labeled ferromagnetic particles using an external magnetic field.
abstract: BACKGROUND
  Our goal was to study the efficacy of liver cancer embolization with magnetically targeted Yttrium-90 labeled ferromagnetic particles and establish the biodistribution profile of these particles.
  
  
  METHODS
  Of twenty rabbits, nine underwent transarterial radioembolization of implanted Vx-2 tumor with increasing 90Y-MTC doses, three were treated with carrier particles alone, four remained untreated and four were sacrificed early to document biodistribution. At various intervals, animals were sacrificed and biodistribution, liver cancer viability and toxicity were measured.
  
  
  RESULTS
  There was a dose related degree of tumor necrosis, with greater than 90 Gy yielding 100% necrosis (baseline 50%). Blood radioactivity one hour post-radioembolization was less than 0.0275 microCi/g. No hematological toxicity was observed. Except for the non-targeted right liver lobe, organ radioactivity levels were within tolerance levels. Significant left (targeted) hepatic lobe necrosis was seen in subjects receiving high doses.
  
  
  CONCLUSIONS
  Hepatic arterial radioembolization with 9Y-MTC bolstered by external magnetic field has significant tumoricidal effect and a favorable biodistribution profile.
authors.affiliation: University of Paris XII Henri Mondor Hospital, Paris, France.
authors.forename: Hicham
authors.initials: H
authors.lastname: Kobeiter
authors.forename: Christos S
authors.initials: CS
authors.lastname: Georgiades
authors.forename: Tina
authors.initials: T
authors.lastname: Leakakos
authors.forename: Michael
authors.initials: M
authors.lastname: Torbenson
authors.forename: Kelvin
authors.initials: K
authors.lastname: Hong
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Geschwind
mesh_terms: D000818:Animals; D004307:Dose-Response Relationship, Radiation; D004621:Embolization, Therapeutic / Q000379:methods*; D005290:Ferric Compounds / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006499:Hepatic Artery; D008114:Liver Neoplasms, Experimental / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D018810:Magnetic Resonance Angiography; D008280:Magnetics / Q000627:therapeutic use*; D008297:Male; D009336:Necrosis; D010316:Particle Size; D011817:Rabbits; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D005290:Ferric Compounds; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes